Asparaginase/daunorubicin/vincristine

Asparaginase/daunorubicin/vincristine Reactions 1704, p52 - 2 Jun 2018 Development of drug resistance: 28 case reports In a study, 28 patients (24 boys and 4 girls) aged 1 17 years [not all ages stated] were described, who developed resistance to asparaginase [L-asparaginase], daunorubicin and vincristine during treatment of T-cell acute lymphoblastic leukaemia (T- ALL) [routes, dosages and time to reaction onset not stated]. The patients, who had T-ALL, started receiving induction phase treatment with four dosages of vincristine, four dosages of daunorubicin and eight dosages of asparaginase from day 1 to day 33. Initially, the favourable treatment response was observed. Subsequently, the patients started receiving consolidation phase treatment with various drugs. After 78 days of the induction therapy, the patients were found to be positive for minimal residual disease analysis along with an over-expression of aldo-keto reductase 1C 1-3 (AKR1C1-3) enzyme, which was considered to be induced by the induction phase of treatment. Based on these findings, development of resistance to vincristine asparaginase and daunorubicin was considered. Author comment: "Further exploring the connection between AKR1C1-3 and the phenomenon of drug resistance, we found that drugs (daunorubicin, vincristine, and asparaginase) used as first-line treatment during induction therapy in paediatric T-ALL induced overexpression/activation of AKR1C1-3." "AKR1C1-3 are overexpressed in T-ALL cells from therapy-resistant patients." Bortolozzi R, et al. AKR1C enzymes sustain therapy resistance in paediatric T- ALL. British Journal of Cancer 118: 985-994, No. 7, Apr 2018. Available from: URL: http://doi.org/10.1038/s41416-018-0014-0 - Italy 803323224 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Asparaginase/daunorubicin/vincristine

Reactions Weekly , Volume 1704 (1) – Jun 2, 2018
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/asparaginase-daunorubicin-vincristine-YtE1lrdYti
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-018-46695-3
Publisher site
See Article on Publisher Site

Abstract

Reactions 1704, p52 - 2 Jun 2018 Development of drug resistance: 28 case reports In a study, 28 patients (24 boys and 4 girls) aged 1 17 years [not all ages stated] were described, who developed resistance to asparaginase [L-asparaginase], daunorubicin and vincristine during treatment of T-cell acute lymphoblastic leukaemia (T- ALL) [routes, dosages and time to reaction onset not stated]. The patients, who had T-ALL, started receiving induction phase treatment with four dosages of vincristine, four dosages of daunorubicin and eight dosages of asparaginase from day 1 to day 33. Initially, the favourable treatment response was observed. Subsequently, the patients started receiving consolidation phase treatment with various drugs. After 78 days of the induction therapy, the patients were found to be positive for minimal residual disease analysis along with an over-expression of aldo-keto reductase 1C 1-3 (AKR1C1-3) enzyme, which was considered to be induced by the induction phase of treatment. Based on these findings, development of resistance to vincristine asparaginase and daunorubicin was considered. Author comment: "Further exploring the connection between AKR1C1-3 and the phenomenon of drug resistance, we found that drugs (daunorubicin, vincristine, and asparaginase) used as first-line treatment during induction therapy in paediatric T-ALL induced overexpression/activation of AKR1C1-3." "AKR1C1-3 are overexpressed in T-ALL cells from therapy-resistant patients." Bortolozzi R, et al. AKR1C enzymes sustain therapy resistance in paediatric T- ALL. British Journal of Cancer 118: 985-994, No. 7, Apr 2018. Available from: URL: http://doi.org/10.1038/s41416-018-0014-0 - Italy 803323224 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704

Journal

Reactions WeeklySpringer Journals

Published: Jun 2, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off